Antisense oligonucleotides (ASOs) and small interfering RNAs (siRNAs) are both tools for modulating gene expression, but they differ in structure, mechanism, delivery, and applications. ASOs are single-stranded molecules designed to bind target RNA and alter its function, while siRNAs are double-stranded molecules that trigger RNA interference (RNAi) to degrade target mRNA. Below is a detailed comparison.
ASO (Antisense Oligonucleotide) |
siRNA (Small Interfering RNA) |
|
Structure |
Single-stranded DNA or RNA molecule. |
Double-stranded RNA molecule with a guide strand and a passenger strand. |
Mechanism of Action |
Binds to target RNA through complementary base pairing, modulating gene expression via RNase H activation or steric hindrance. |
Binds perfectly complementary RNA, inducing target mRNA cleavage via the RISC complex. |
Delivery |
Delivered as single molecules; typically conjugated with ligands like GalNAc for targeted delivery. |
Delivered as duplex RNA; often formulated with nanoparticles or lipid-based carriers. |
Target Specificity |
Can target both pre-mRNA (splicing modulation) and mature mRNA. |
Targets mature mRNA only due to its mechanism requiring perfect complementarity. |
Applications |
Splicing modulation, gene knockdown, and disease-specific RNA regulation. |
Gene silencing through degradation of specific mRNA. |
Stability |
Chemically modified for increased nuclease resistance and longer half-life. |
Less stable due to inherent susceptibility to nuclease degradation. |
Tissue Targeting |
Can be targeted to specific tissues, such as liver or CNS, via chemical conjugates. |
Typically relies on delivery systems for effective tissue targeting. |
Examples |
Nusinersen, Mipomersen, Eteplirsen. |
ONPATTRO (Patisiran), GIVLAARI (Givosiran). |
ASOs and siRNAs are complementary tools in therapeutic development, each with unique advantages. ASOs offer versatility in targeting both pre-mRNA and mature RNA, enabling broader applications like splicing modulation. In contrast, siRNAs are highly effective for precise mRNA degradation through RNAi. Advances in chemistry and delivery technologies have expanded their therapeutic potential, making both ASOs and siRNAs valuable in addressing a variety of diseases.
REQUEST A QUOTE | ||
---|---|---|
PHONE | ONLINE FORM | |
[email protected] | +1 408-828-0438 | ONLINE QUOTE SUBMISSION |